We are live on ! Find out more
QNTM

Quantum Biopharma Class B Subordinate Voting Shares

14 hedge funds and large institutions have $553K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

116% more capital invested

Capital invested by funds: $256K → $553K (+$296K)

56% more funds holding

Funds holding: 914 (+5)

0.01% more ownership

Funds ownership: 3.63%3.64% (+0.01%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
2
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

QNTM Hedge Fund Activity: Q1 2025 in Review

14 of the 7,462 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q1 2025, worth a combined $553K — up 116% from $256K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new QNTM positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was J.W. Cole Advisors, opening a new position worth an estimated $72.4K. The largest seller was AdvisorShares Investments, cutting an estimated $115K.

  • 14 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q1 2025, up from 9 in Q4 2024.
  • Funds reported $553K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q1 2025, up 116% quarter-over-quarter.
  • 7 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q1 2025 and 2 closed out, a net change of +5 holders.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q1 2025 was J.W. Cole Advisors, an estimated $72.4K added.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q1 2025 was AdvisorShares Investments, an estimated $115K sold.

Based on aggregated 13F filings for Q1 2025.